After looking into PLX the main contributing factor was the people involved. They had investors which were extremely successful with previous ventures and that was good enough for investors. They were a start up company and bought a shell from Orthodontix on th AMEX which was bought out. Now the y are about to go to clinical trials, and they have been compared to Dendreon and Imclone. At this early stage of our company, the difference with us is we won't find out later that a drug we created has harmful side effects. We are selling the technology only. It has already been proven.
News 
Market Data 
Discover 
